Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure  by Summers, Angela M. et al.
Kidney International, Vol. 68 (2005), pp. 2381–2388
Single-center experience of encapsulating peritoneal sclerosis in
patients on peritoneal dialysis for end-stage renal failure
ANGELA M. SUMMERS, MARC J. CLANCY, FYSAL SYED, NICOLA HARWOOD, PAUL E.C. BRENCHLEY,
TITUS AUGUSTINE, HANY RIAD, ALASTAIR J. HUTCHISON, PAUL TAYLOR, ROBERT PEARSON,
and RAM GOKAL
Departments of Renal Medicine, Surgery and Transplantation, and Radiology, Manchester Institute of Nephrology and
Transplantation, Manchester Royal Inﬁrmary, Manchester, United Kingdom
Single-center experience of encapsulating peritoneal sclerosis
inpatients on peritoneal dialysis for end-stage renal failure.
Background. Encapsulating peritoneal sclerosis (EPS) is a
rare but serious complication in patients undergoing contin-
uous ambulatory peritoneal dialysis (CAPD) or automated
peritoneal dialysis (APD). It is characterized by a progressive,
intra-abdominal, inflammatory process resulting in sheets of fi-
brous tissue that cover, bind, and constrict the viscera, thereby
compromising the motility and function of the bowel. Although
recent therapeutic approaches have been reported with variable
success, the ability to detect reliably at an early stage patients
at risk for EPS would be beneficial and allow treatment stan-
dardization. The aim of this study was to evaluate the clinical
features of EPS and identify possible risk factors for its devel-
opment in CAPD and APD patients.
Methods. This was a review of all cases of EPS in a single
center over the last 5 years.
Results. There were 810 CAPD and APD patients, managed
in our program over this period. We identified 27 cases of EPS,
giving an overall of 3.3% in this population. The mean duration
of CAPD before diagnosis of EPS was 72.6±39.7 months (range
16–172). Sixteen cases required surgical treatment and were
classified as severe; others were treated conservatively (mild to
moderate group). Ten patients received tamoxifen treatment
with apparent benefit. The overall mortality rate was 29.6%.
Eight patients from the severe group and the entire moderate
group survived on hemodialysis or transplantation at 48.71 and
27.63 months follow-up, respectively. Peritonitis rates were not
different between the 2 groups and peritoneal history was un-
remarkable compared to overall peritonitis rates in the unit.
Data on small solute transport were not available in all patients
in this retrospective analysis.
Conclusion. EPS is a serious, life-threatening complication
of CAPD. Most cases had PD duration of more than 4 years.
Careful monitoring by CT scans of the peritoneal membrane in
patients beyond 5 years, and early catheter removal in patients
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with peritoneal thickening should be considered for long-term
CAPD patients. Treatment with tamoxifen may be of benefit in
these patients.
Encapsulating peritoneal sclerosis (EPS), first de-
scribed by Gandhi [1], is a rare but serious complication
of peritoneal dialysis (PD), and is life threatening in these
patients. The optimum definition of EPS is still debated
and the diagnostic criteria used to produce epidemiologic
data are by no means uniform [2]. Due to its rarity and
the relatively long duration of dialysis prior to its devel-
opment, there is no satisfactory estimate of the incidence
of dialysis-related EPS. Prevalence estimates range from
0.54 to 7.3% [2], while the Japanese experience suggests
an overall incidence of 0.9% between 1980 and 1996 [3],
and 2.5% from a prospective multicenter study in the late
1990s [4].
EPS is an extremely serious condition with a reported
mortality of up to 93%–60% of patients die within
4 months in severe cases with complete intestinal ob-
struction. Originally known as sclerosing encapsulating
peritonitis (SEP), an International Society of Peritoneal
Dialysis subcommittee recommended the use of EPS be-
cause the old terminology implied infection as a major
cause [2]. The early diagnosis and treatment prior to de-
velopment of symptoms is difficult. Although it is very
important to detect the patients at increased risk of de-
veloping EPS, there are no known clinical predictors [2,
5]. In patients on peritoneal dialysis, early signs include
loss of ultrafiltration and development of high transporter
status, probably due to increased peritoneal membrane
permeability, which may in itself be a risk factor [6]. One
factor linked with the development of the syndrome is du-
ration of therapy. In Australia, an incidence of nearly 20%
after 8 years of dialysis has been described [7]. Peritoni-
tis [2, 3, 8] and prolonged use of unphysiologic solutions
have also been implicated [9–11].
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The hallmark of the condition is peritoneal fibrosis and
thickening. A recent analysis from an International Peri-
toneal Biopsy registry shows that thickening of the mem-
brane usually occurs after 4 or 5 years of PD and is as-
sociated with increasing severity of vasculopathy; these
findings are not invariably found with long duration of
therapy [12]. It is likely that this process continues to
eventually produce EPS, although there is no evidence
for this.
There are classic clinical, radiologic, macroscopic, and
pathologic appearances in advanced cases, represented at
laparotomy by intestinal cocooning. In such cases symp-
toms result from impairment of gut motility due to bind-
ing of the intestinal loops to each other, other viscera,
and the internal surface of the abdominal wall by an ag-
gressive fibrotic process. This produces partial or total ob-
struction, giving colicky pain, vomiting, bloating, diarrhea
(caused when the partial obstruction spontaneously re-
solves), and weight loss with malnutrition [2]. If obstruc-
tion of the intestine does not resolve, intestinal dilatation
and mural ischemia may develop, resulting in bacterial
translocation, systemic inflammatory response syndrome
(SIRS), sepsis, or even frank peritonitis [8]. This progres-
sion is frequently fatal without surgical treatment and,
unfortunately, many patients reach this stage before the
diagnosis is confirmed [13, 14].
The Japanese experience has been very helpful in the
understanding of the process and its management. Var-
ious phases to the disorder are outlined [15]. After the
development of EPS is confirmed, the authors advocated
initial steroid treatment immediately after onset (inflam-
matory stage). If steroid therapy was ineffective, the dose
was decreased immediately and followed (encapsulat-
ing stage) by management with total parenteral nutri-
tion (TPN). If ileus symptoms remained (ileus stage),
active laparotomy and total intestinal enterolysis was
performed. During surgical treatment of EPS, it is im-
portant to perform total enterolysis without damaging
the capsule-covered intestine. This is an interesting ap-
proach but it is not clear how one clinically defines these
stages, unless laparotomy and histologic diagnosis are
available.
The purpose of this study was to evaluate the clinical
characteristics of EPS patients, and to look for early clini-
cal features that may be associated with EPS in peritoneal
dialysis (PD) patients.
METHODS
This study reports all cases of EPS diagnosed at Manch-
ester Royal Infirmary between 1998 and 2003. Clini-
cal records were reviewed in detail and individual data
sheets compiled. Information was entered into a standard
database program, Microsoft Access (Microsoft, Red-
mond, WA, USA), and further variables calculated, in-
cluding total duration of PD and graft survival for those
transplanted.
Diagnosis
The patients were arbitrarily divided into 2 categories:
severe and mild/moderate. The major diagnostic criteria
for the severe group were need for surgery for exten-
sive symptoms and signs of intractable intestinal obstruc-
tion, gut ischemia, or gut-related sepsis. These included
the presence of significant gastroenterologic symptoms
and signs (abdominal pain, vomiting, weight loss, absent
bowel sounds, and palpable intestinal mass) with appear-
ances of EPS at laparotomy (Table 1). Radiologic diag-
nosis entailed a CT scan.
Peritoneal calcification
Computed tomography (CT) findings showed peri-
toneal thickening and features of significant bowel
pathology as exemplified by bowel dilatation, calcifica-
tion, septation, and nodularity, each of which were clas-
sified + to +++ with increasing severity. CT findings
were not essential for the diagnosis of EPS but were
confirmatory. Several CT scans were done months be-
fore the clinical diagnosis (ID S14 and S16 in the se-
vere group whose CT scans show little evidence of severe
disease).
Diagnosis of the mild to moderate EPS was made by
biopsy at laparotomy (at Tenckoff removal) or by CT
scans findings. M4, M9, and M11 had clinical symptoms of
vomiting or intermittent abdominal pain that prompted
the suspicion that EPS was present; this was subsequently
confirmed by CT (Table 2).
Statistics
Group outcome differences were compared with the
t test for independent samples, the Mann-Whitney test,
and the Fisher exact probability test where appropriate.
Multi-regression analysis was not possible because of the
small number of patients in the group.
RESULTS
Demographics
Twenty-seven patients were identified from surgical au-
dit records and the renal unit database. Our PD popula-
tion over this time period comprised 810 patients; this
represents 3.3% of PD patients attending for their care
at our center over this period.
Of the 27 patients in whom a diagnosis of EPS was
made between August 1996 and July 2003, 11 were male
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and 16 female with a mean age of 42 years (SD 13 years).
These patients exhibited wide variety in the causes of
their chronic renal failure with no predominant diagnosis.
Patient groups
We divided the patients into 2 groups. The first group,
termed severe, comprised EPS patients who developed
any standard surgical indication for laparotomy (peri-
tonitis, intractable intestinal obstruction, gut ischemia,
or gut-related sepsis). The second group, termed mild or
moderate, were the remaining patients, where the diag-
nosis was (1) attributable to clinical and radiologic fea-
tures but the patients did not require surgery for their
gastrointestinal manifestations, or (2) patients who had
attributable symptoms and similar macroscopic changes
at laparoscopy or laparoscopy for other indications (e.g.,
cholecystectomy, Tenckoff replacement). Both groups
had the same macroscopic pathologic process identified
within their peritoneal cavity. CT scans were used to aid
diagnosis, but it is apparent that these were not discrim-
inatory enough for a definitive diagnosis based on CT
alone; our arbitrary definition of severity of EPS (Tables
1 and 2) showed overlap with severe cases by CT (M3 and
M8) appearing in the mild/moderate group, whereas S14
and S16 had very little change on CT. The latter 2 cases
had their CT scans done several months before surgery
and it is likely that the disease process progressed. In
the mild to moderate group there were 3 patients (M4,
M9, M11) who were asymptomatic but had significant
peritoneal thickening on CT. It is questionable whether
these patients had EPS or peritoneal thickening asso-
ciated with long-term PD treatment. CT scans in these
patients were done as part of our routine screening mea-
sures, established after the initial cases, in our long term
(>5 years on PD). While not representing the full blown
clinically based EPS picture, they represent a state where
there is potential for development of the EPS picture. As
such, the future management was discussed with each pa-
tient; this entailed options of remaining on PD therapy, a
change in dialysis therapy to hemodialysis, and treatment
with tamoxifen. These 3 opted for change to HD and
were included in the mild group. Patient M7 was found
to have peritoneal sclerosis on laparotomy but opted
to stay on PD with tamoxifen treatment. He remains
well on PD over 37 months after the diagnosis with no
change in his clinical or CT scans over this postdiagnosis
period.
Sixteen patients fell into the severe category, including
3 patients who were not offered surgery due to comor-
bidity and very poor clinical state, but in whom the indi-
cations for laparotomy were nevertheless present—these
3 patients died. Eleven patients were defined as having
mild to moderate EPS, 1 of whom underwent laparotomy
performed with a view to pancreas transplantation; the
Table 3. Organisms causing peritonitis in EPS patients
Organism causing Number of
peritonitis episodes
Not defined 15
Staphylococcus aureus 11
Coagulase negative staphylococcus 9
Diptheroids 4
Streptococcus 4
Multiple growth 3
Coliform 2
Hemophillus inﬂuenza 1
Tuberculococcus 1
Other 3
intra-abdominal features of EPS became evident and the
transplant was subsequently performed.
Time on CAPD
The mean duration of CAPD, overall, was 72.6 months
(SD 39.7 months). There was a significantly longer mean
duration of PD in the severe group, 84.3 months com-
pared with 55.6 months in the mild to moderate group
(P = 0.040, Mann Whitney, P = 0.032, t test). Patients
had an average of 2.62 PD (SD 2.2) catheters in their life-
time on PD. There was no significant difference in patient
age or mean number of PD catheters inserted per patient.
Time since diagnosis (survivors)
The mean time since diagnosis in the surviving patients
originally classified as “severe” was 48.71 months. The
mean survival time since diagnosis of patients in the mild
to moderate group is 27.63 months.
Peritonitis
There were a total of 71 episodes of peritonitis di-
agnosed during the period of peritoneal dialysis, giving
an overall peritonitis rate of 1 episode every 27 patient
months of therapy. The organisms responsible for the
peritonitis are shown in Table 3, the most common be-
ing Staphylococcus aureus, followed by Coagulase neg-
ative staphylococci. There was no significant difference
in the peritonitis rates between the 2 groups (severe, 1
episode/28 patient months; mild-moderate, 1 episode/25
patient months). There was a greater mean number of
peritonitis episodes in the severe group, 3.1 compared
with 2.0 per patient, and this was not statistically signif-
icant. The unit’s overall peritonitis rate over this period
was roughly 1 episode per 20 to 30 patient months.
Treatment and outcome
Once a diagnosis of EPS was made 13 patients un-
derwent laparotomies for acute surgical indications.
There were 4 perioperative deaths, giving an overall
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surgical mortality of 31%. Two patients also had Sepra-
coat, which is a 0.4% solution of hyaluronic acid in
a phosphate-buffered saline infused into the peritoneal
cavity through a cannula placed at one end of the la-
parotomy incision during final closure. It is intended to
reduce postoperative formation of de novo adhesions re-
sulting from incidental tissue damage in abdominal/pelvic
surgery. Various medical treatments for EPS were pre-
scribed to different patients, including tamoxifen (10),
prednisolone (2), cyclosporine (1), and rapamycin (2).
In the severe group, 8 patients died, 3 of whom did not
have surgical intervention. Two received specific ther-
apy (tamoxifen and rapamycin). Both these patients had
extremely severe disease with extensive postoperative
complications of intra-abdominal sepsis/fistula and per-
sistent obstruction. The patients with severe EPS who
underwent major laparotomy were found to benefit from
several weeks of nasogastric aspiration, IV feeding, and
daily HD. Of the 9 survivors in this severe group, 6 re-
ceived specific therapy. All of the survivors were main-
tained successfully on hemodialysis (5 patients) or trans-
plantation (3 patients) at a mean duration of 27.63 months
postdiagnosis, with no further complications. Intergroup
comparison of requirement for TPN revealed an in-
creased requirement in the severe group that was sig-
nificant (P = 0.005), as well as a significantly decreased
overall survival (P = 0.005). Of the 27 patients, 13 re-
quired total parenteral nutrition, 11 perioperatively and
2 for nutritional support without surgery.
In the mild-moderate group of 11 patients, all were
alive for a mean period of 48.71 months since diagnosis.
All but 2 were on hemodialysis, 1 with a successful trans-
plant and 1 patient continued on PD and tamoxifen with
improved ultrafiltration and adequate dialysis 26 months
since diagnosis (made at laparotomy for cholecystectomy;
peritoneal biopsy confirmed EPS). It is possible that in
this patient there was regression of the fibrotic process
and represented a very mild form of the disease. At la-
parotomy significant fibrosis was evident but the patient
wanted to remain on PD; hence, the decision to con-
tinue. A recent CT scan showed no evidence of signif-
icant peritoneal thickening. Four patients in this group
have been on long-term tamoxifen at a dose of 10 mg
daily.
In total, 8 of 27 patients died as a result of EPS, giving
an overall mortality of 29.6%. All the deaths were in the
severe group. Most survivors continued on hemodialysis
or had renal transplants with no significant abdominal
symptoms.
DISCUSSION
Peritoneal fibrosing syndromes include a spectrum of
changes present in PD patients ranging from a thickened
peritoneum to EPS. EPS is a rare but serious complication
with a high mortality rate [2, 7]. In this study we report
on 27 cases in which the disease process has produced in-
testinal compromise and symptoms. In dividing the cases
into those with indications for urgent surgery (severe)
and those in whom the diagnosis was made radiologically
or by laparotomy for other indications (mild to moderate
group), we highlight that there is a spectrum of severity
in this condition. The severe cases indeed represent the
more advanced stages, and the high mortality reflects the
extensive fibrotic process and the various pathologic se-
quelae. The large numbers of severe cases identified at
our unit has led to an increased awareness and index of
suspicion regarding this condition. This has, in turn, led
to more aggressive investigation of PD patients with sus-
picious symptoms, usually by CT, allowing us to identify
a number of cases of EPS of mild to moderate severity.
While there is no proof that early intervention (discon-
tinuation of PD and use of tamoxifen) in this group led
to the resolution of the problem, we believe that as a
precautionary measure, stopping PD and early tamox-
ifen may well have helped. The experiment was limited
as it was not possible to randomize patients to various op-
tions. None of the cases in the mild-moderate group have
so far developed intestinal problems requiring surgery,
and all remain well after a mean period of 35 months’
postdiagnosis.
EPS has also been linked with the nature of dialy-
sis solution used. Peritoneal dialysis solutions are un-
physiologic in having low pH and high osmolality. The
peritoneum undergoes thickening of the peritoneal in-
terstitium and basement membrane reduplication in the
mesothelium, as well as in the capillaries. Such changes
have been judged to occur secondarily to the unphysio-
logic composition of the dialysis solutions, and also the
direct action of glucose [16] and glucose degradation
products, which bring about advanced glycosylation end
product (AGE) related changes in the peritoneal mem-
brane [10]. Some of the changes are diabetiform in
nature, with alterations of peritoneal microvessels and
neovascularization [9]. Glucose degradation products
(GDP) are generated during the sterilization process [17].
All of these factors are potentially harmful to the peri-
toneal membrane.
In keeping with previous reports, the majority of symp-
toms reported were those resulting from partial or to-
tal occlusion of the intestinal lumen [14], namely pain
(usually colic), vomiting, abdominal distension, or weight
loss. In the severe cases, necessity for surgical treatment
was caused by complete intestinal obstruction, secondary
peritonitis, gut-related sepsis, or gut ischemia. Invariably,
these patients underwent a trial of conservative treatment
that failed to resolve their acute symptoms and signs. De-
spite some similarity in acute presentation, these patients
had a progressive, intra-abdominal fibrosing pathol-
ogy that is distinct from the more common peritoneal
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adhesions. The risk of progression to the sequelae listed
above is seemingly higher.
Our study confirms the link between duration of PD
and likelihood of manifesting EPS, originally suggested
by the study of Rigby and Hawley [7], which showed an
incidence of 1.9%, 6.4%, 10.8%, and 19.4% after 2, 5, 6,
and 8 years of PD, respectively. In our series, patients had
a significantly higher mean duration of PD in the severe
group compared with the mild to moderate. This evidence
makes a strong case for the condition being caused, or
driven by, the effects of PD, rather than some non-PD
related factor. In addition to the link with PD duration,
studies have shown a link between frequency of peritoni-
tis and probability of developing EPS [2, 3, 8]. Our data do
not support this hypothesis as the peritonitis rates were
not particularly high in these patients, nor were the rates
significantly different between the severe and the mild-
moderate group. It is feasible that the episodes of infec-
tion may have varied widely in severity and/or duration
but these details could not be accurately identified. As
previously noted in various studies, Staphylococcus au-
reus is a major bacterial pathogen, being responsible for
11 of 54 episodes in our series. This coagulase-positive or-
ganism produces enzymic activity capable of converting
fibrinogen to fibrin, the major matrix component of in-
testinal adhesions. As infection rates with Staphylococcus
aureus are higher in the EPS patients, one potential inter-
vention in long-term PD patients could include prophy-
lactic antibiotics to prevent infection with this organism;
in our unit, all patients undergo exit site prophylaxis with
mupirocin and this has shown significant reduction in S.
aureus exit site infections and peritonitis [18]. Coagulase
negative staphylococcus is the second most common in-
fectious organism in all reported series with a variety of
other bacteria identified in small numbers of cases; this
was again verified in this study. The original reports of
an intestinal “cocoon” were caused by intestinal tuber-
culosis [19]. This organism was identified in only 1 of our
patients. No cases of fungal peritonitis were identified in
this sample despite previous reported association of EPS
and fungal peritonitis [20].
Diagnostic imaging has an important role and may be
the only way to diagnose EPS without a laparotomy. It
may be the earliest indicator of EPS with the presence
of thickening. CT has the major advantage of visualizing
the peritoneum and providing information on thickness.
Valuable diagnostic information can also be obtained
from the relationship of intestinal loops and the presence
or absence of intra-abdominal fluid collections. Similar
information is probably obtainable from ultrasound in
severe cases, but it is arguable that the diagnosis is likely
to be obvious clinically once things reach this stage. Ra-
diologic investigations confirmed the diagnosis in 7 of
the 10 patients in the mild to moderate group. However,
our arbitrarily defined criteria were not that discrimina-
tory to classify all the cases correctly into the severe and
mild to moderate groups. It is clear that EPS represents
a range of pathologic states, and no 1 diagnostic criterion
is going to suffice. Keen clinical suspicion and awareness
of the problem in patients at risk is as important as the
various investigations. It is apparent that CT scan alone
cannot be the sole criteria for the diagnosis of EPS—it
needs a clinical component. The finding of thickening of
the peritoneum on CT scans does highlight the poten-
tial risk of progression to the full-blown EPS picture, and
there is a need to address this with patients and form the
basis of any ‘informed’ changes to therapy and greater
vigilance. CT was the major imaging modality, but ultra-
sound, plain, and contrast radiography were also used to
identify peritoneal thickening, fluid collections, and com-
plete or partial intestinal obstruction.
An alternative approach to disease definition and early
identification is analysis of the relationship between de-
crease in effectiveness of dialysis, as measured by de-
velopment of a hyperpermeable membrane and loss of
ultrafiltration [21]. Complete data on ultrafiltation mea-
surements prior to diagnosis of EPS were not obtainable
for this sample, but in our study PD was stopped in all pa-
tients at or prior to diagnosis except 1 who continues on
PD and tamoxifen. Continuation of PD even following
extensive surgery for EPS has been successful [22]. It is
proposed that given the association shown by our study
between severity and total duration of PD and the previ-
ous successful case reports of treatment by peritoneal rest
[7, 8, 13, 23–28] that wherever possible, patients should
be switched to hemodialysis or transplanted at diagno-
sis. However, even removing the putative driving force
for the disease process by withdrawing PD is not always
successful [29].
Evaluation of medical treatments for EPS is difficult.
Virtually the entire literature is based on anecdotal case
reports and any kind of structured study is rare. Candi-
date treatments have included immunosuppression with
steroids, azathioprine and cyclosporine, enteric rest with
TPN and, most recently, tamoxifen. Immunosuppression
has produced clinical improvement in isolated cases and
small series [7, 23, 24, 28, 30] as well as being associated
with increased survival [31, 32], while tamoxifen has been
successfully used [33].
Tamoxifen’s effect on transforming growth factor beta
(TGF-b) in the ovary [34] and in vitro [35] must be borne
in mind alongside its anecdotal successes. It has, how-
ever, been widely reported as successful in the treat-
ment of retroperitoneal fibrosis [36–38], but how well
this translates to EPS is unclear. A recent report of
its ‘prophylactic’ use in 9 cases of peritoneal sclerosis
showed that none developed EPS, while in the con-
trol group of 14 patients with sclerosis 4 developed
the syndrome and 3 died [39]. In our study, the use
of tamoxifen may provide some benefit, especially in
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the mild-moderate group, but this cannot be stated
categorically until further CT scans and long-term follow-
up data are available. Prospective data will continue to
be collected on these patients.
Many other therapies have been proposed with vari-
able results. In anecdotal reports or limited series, TPN
and surgery (alone or in combination) have been associ-
ated with improved survival. Bhandari et al [40] recom-
mended immunosuppression before surgery. TPN alone
has no benefit [6], but needs to be used in combination
with surgery, usually prior to it. Our experience would
concur with this.
Given that the pathologic lesions characterizing the
disease result from the deposition of largely acellu-
lar material (mainly extracellular matrix proteins like
fibrin and collagen), it is perhaps questionable to use
agents that are demonstrably profibrotic, such as cy-
closporine [41]. Newer immunosuppressives such as
mycophenylate-mofetil and rapamycin are believed to
have less profibrotic profiles [42] and would certainly
be candidate therapies. There is currently a wide vari-
ety of experimental antifibrotic agents, such as antibod-
ies to the profibrotic cytokine, TGF-b [43] or peptides
which inhibit its activation [44], under investigation. It is
hoped that such agents may provide future therapeutic
options.
From our experience and that in the literature we
would suggest that the optimum management of this con-
dition entails great awareness and high index of suspicion
to identify a subclinical disease process. This can be ap-
proached by investigation of the population at risk—long
term (>5 years on PD) with high transporter status and
loss of ultrafiltration. Appropriate investigations include
imaging (CT scan for fibrosis, thickening, and calcifica-
tion) and perhaps regular peritoneal equilibration tests.
This study does not provide evidence for this. EPS has
been associated with high transporter status, which occurs
with long-term PD, and may be a further marker, and this,
however, is questionable as there have been some reports
of patients with low solute transport developing EPS. The
optimum medical treatment is at present unclear, but our
experience, though anecdotal, supports the use of tamox-
ifen. Potentially profibrotic effects of concomitant medi-
cations should be considered. Change of dialysis method
to hemodialysis or transplantation should be instigated
at diagnosis, if possible, to reduce disease progression. In
cases of EPS with obstruction, aggressive nutritional sup-
port must be given to any at risk patient. Most patients
having a trial of conservative management for obstructive
symptoms should receive TPN. At surgery, meticulous
surgical technique to avoid enterotomies is vital. These
are the main source of operative morbidity and mortality
through the production of fistulas and sepsis.
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